MENU

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease

Sotzny, F; Blanco, J; Capelli, E; Castro-Marrero, J; Steiner, S; Murovska, M; Scheibenbogen, C

AUTOIMMUNITY REVIEWS
2018
VL / 17 - BP / 601 - EP / 609
abstract
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a frequent and severe chronic disease drastically impairing life quality. The underlying pathomechanism is incompletely understood yet but there is convincing evidence that in at least a subset of patients ME/CFS has an autoimmune etiology. In this review, we will discuss current autoimmune aspects for ME/CFS. Immune dysregulation in ME/CFS has been frequently described including changes in cytokine profiles and immunoglobulin levels, T- and B-cell phenotype and a decrease of natural killer cell cytotoxicity. Moreover, autoantibodies against various antigens including neurotransmitter receptors have been recently identified in ME/CFS individuals by several groups. Consistently, clinical trials from Norway have shown that B-cell depletion with rituximab results in clinical benefits in about half of ME/CFS patients. Furthermore, recent studies have provided evidence for severe metabolic disturbances presumably mediated by serum autoantibodies in ME/CFS. Therefore, further efforts are required to delineate the role of autoantibodies in the onset and pathomechanisms of ME/CFS in order to better understand and properly treat this disease. (C) 2018 The Author(s). Published by Elsevier B.V.

AccesS level

Green Published, Other Gold, Green Accepted

Mentions data

PAPER MENTIONS
Immunology
  •   Twitter
  • 334
  •   Wikipedia
  • 1
  •   News
  • 12
  •   Policy
  • 0

Mentions Chart

Influratio by dimension
  • Twitter
  • Wikipedia
  • News
  • Policy
PAPER MENTIONS
  •   Twitter
  • 334
  •   Wikipedia
  • 1
  •   News
  • 12
  •   Policy
  • 0
PROYECTO FINANCIADO POR PLAN NACIONAL DE INVESTIGACIÓN AGENCIA ESTATAL DE INVESTIGACIÓN, MINISTERIO DE CIENCIA E INNOVACIÓN. PID2019-109127RB-I00